B+
Bull case
20%
Probability
Target price
$88.77
+59.9% vs current
CGON
CG OncologyCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$63.80
+14.9% vs current
B-
Bear case
20%
Probability
Target price
$38.84
-30.1% vs current
AI sentiment snapshot
Latest data as of 2026-01-10
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+64.0
Score
AI commentary
Market sentiment appears mixed-to-cautious with several third-party price-targets showing a wide range, indicating dispersion among analysts [#SERP-1] and aggregator sites showing varied medians [#SERP-3]. Short-term tone is event-driven and sensitive to clinical/operational news; investor focus is on binary milestones and cash runway. External targets were consulted only as a reference against the anchor-driven scenarios [#SERP-2].
RankAlpha Sentiment AI - 2026-01-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventClinical data readout (assumed window end)High impact
Potential binary clinical readout or cohort update that would drive large directional moves; date is an assumed end-of-window where specifics are not public—assumption noted here [#SERP-1].
2026-04-10catalystNear-term operational / earnings updateHigh impact
Quarterly operational or cash-runway update expected in the near term; could materially re-rate shares if guidance deviates from current expectations (assumed date used where no public date available) [#SERP-3].
2027-01-10catalystPartnership / regulatory progressHigh impact
Potential longer-term value creation from partnerships, licensing, or regulatory milestones; timing estimated conservatively when not publicly disclosed.
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-10 • Updated nightlySource: Internal modelMethodology